Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Gross Profit (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Gross Profit for 4 consecutive years, with $503855.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 44.65% to $503855.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.9 million, a 42.47% decrease, with the full-year FY2024 number at $3.4 million, up 326.79% from a year prior.
  • Gross Profit was $503855.0 for Q3 2025 at bioAffinity Technologies, up from $252881.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $989942.0 in Q2 2024 to a low of $834.0 in Q1 2023.
  • A 4-year average of $386926.4 and a median of $369309.0 in 2025 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: skyrocketed 99774.1% in 2024, then crashed 74.45% in 2025.
  • bioAffinity Technologies' Gross Profit stood at $2171.0 in 2022, then surged by 25164.72% to $548497.0 in 2023, then grew by 17.67% to $645427.0 in 2024, then fell by 21.93% to $503855.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Gross Profit are $503855.0 (Q3 2025), $252881.0 (Q2 2025), and $485737.0 (Q1 2025).